Eton Pharmaceuticals (NASDAQ:ETON) announced its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.12, Morningstar.com reports.
Eton Pharmaceuticals stock traded up $0.20 during mid-day trading on Wednesday, hitting $6.22. The company’s stock had a trading volume of 31,509 shares, compared to its average volume of 44,466. The stock’s 50 day moving average is $7.13. The firm has a market cap of $109.65 million and a P/E ratio of -1.07. The company has a current ratio of 5.89, a quick ratio of 5.89 and a debt-to-equity ratio of 0.01. Eton Pharmaceuticals has a 52-week low of $5.70 and a 52-week high of $10.20.
In other Eton Pharmaceuticals news, CEO Sean Brynjelsen acquired 10,000 shares of Eton Pharmaceuticals stock in a transaction that occurred on Tuesday, May 21st. The stock was purchased at an average cost of $7.93 per share, with a total value of $79,300.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 13.46% of the stock is currently owned by corporate insiders.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
Read More: How a Put Option Works
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.